Search Results - interleukin

4 Results

Sort By:

Anti-bacterial Treatments Using Peptide-Based Inhibitors of the STAT3-IL10 Pathway

Abstract: Tuberculosis (TB) is an infectious disease that typically affects the lungs. Current therapies include a panel of antibiotics given over a range of 6-9 months. As a result of the expense of treatment, the extended timeframe needed for effective treatment, and the scarcity of medicines in some developing countries, patient compliance with TB...

Published: 4/8/2024 | Inventor(s): Nadya Tarasova, Mercedes Gonzalez-Juarreto

Keywords(s): Anti-infective, IL-10, immunomodulatory, Immunotherapy, INTERLEUKIN, STAT3, TUBERCULOSIS

Category(s): Application > Therapeutics, Collaboration Sought > Licensing, Collaboration Sought > Collaboration, TherapeuticArea > Immunology, TherapeuticArea > Infectious Disease

Peptide Inhibitors for Viral Infections and as Anti-inflammatory Agents

Abstract: IFN-gamma and IL-10 are cytokine signaling molecules that play fundamental roles in inflammation, cancer growth and autoimmune diseases. Unfortunately, there are no specific inhibitors of IFN-gamma or IL-10 on the market to date. NCI investigators at the Cancer and Inflammation Program have synthesized short peptides that selectively interfere...

Published: 4/8/2024 | Inventor(s): Nadya Tarasova, Giorgio Trinchieri, Howard Young, C. Andrew Stewart, Marco Cardone, Alan Perantoni

Keywords(s): IFN-gamma, Interferon gamma, INTERLEUKIN, Peptide, Peptidometic, psoriasis, Synthetic Peptide Inhibitors

Category(s): Collaboration Sought > Collaboration, TherapeuticArea > Dermatology, Collaboration Sought > Licensing, Application > Therapeutics, TherapeuticArea > Oncology, TherapeuticArea > Infectious Disease, TherapeuticArea > Immunology

Transgenic Human Interleukin-21 Mouse Model

Available for licensing is a mouse model that constitutively expresses human interleukin-21 (IL-21). Traditionally, human IL-21 transgenic mouse models are difficult to produce as those with high IL-21 levels exhibit growth retardation and die before sexual maturity. The investigators generated transgenic mice that express human IL-21, which can stimulate...

Published: 10/28/2024 | Inventor(s): Katsutoshi Ozaki, Warren Leonard

Keywords(s): AC5XXX, ACXXXX, AXXXXX, CCXXXX, CXXXXX, IDXXXX, IL-21, INTERLEUKIN, interleukin 21, IXXXXX, Mice, Mouse, Mouse animal model, mouse model, TRANSGENIC

Category(s): Collaboration Sought > Licensing, Application > Research Materials, Application > Diagnostics, TherapeuticArea > Oncology, Application > Therapeutics

Muramyl Dipeptide as a Therapeutic Agent for Inflammation

The nucleotide-binding oligomerization domain 2 (NOD2) protein plays a key role in innate immunity as a sensor of muramyl dipeptide (MDP), a breakdown product of bacterial peptidoglycan. Bacterial peptidoglycan promotes the innate immune response through the activation of Toll-like receptor 2 (TLR2), which ultimately provokes inflammation. Activation...

Published: 10/28/2024 | Inventor(s): Warren Strober

Keywords(s): Autoimmune, AUTOIMMUNE DISEASE, Autoimmune disorder, Autoimmunity, BBXXXX, BCXXXX, BOWEL, Crohn disease; Inflammatory bowel disease 1, Crohn's disease, Dipeptide, IB3XXX, IBD, IBXXXX, IL-12, Inflammation, INFLAMMATORY, inflammatory bowel disease, Inflammatory bowel disease 1, inflammatory disease, INTERLEUKIN, INTERLEUKIN-12, IRF4, IXXXXX, MDP, Muramyl, NOD2, peptidoglycan, TLR, TLR2, Toll-like, Toll-like receptors, Ulcerative Colitis

Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, Application > Therapeutics, TherapeuticArea > Immunology, Application > Research Materials, Application > Diagnostics